Who are Bifonazole spray once daily's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Topical Clotrimazole cream, Canesten®, Ketoconazole 2%, Terconazole Vaginal Suppository, Voriconazole clinical practice, fast itraconazole tablet.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bifonazole-spray-once-daily.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Bifonazole spray once daily — Competitive Intelligence Brief

Bifonazole spray once daily (Bifonazole spray once daily) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: azole antifungal. Area: Infectious Diseases.

phase 2 azole antifungal lanosterol 14α-demethylase Infectious Diseases Small molecule Live · refreshed every 30 min

Target snapshot

Bifonazole spray once daily (Bifonazole spray once daily) — Bayer. Bifonazole is an antifungal agent that works by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Bifonazole spray once daily TARGET	Bifonazole spray once daily	Bayer	phase 2	azole antifungal	lanosterol 14α-demethylase
Topical Clotrimazole cream	Topical Clotrimazole cream	Hayat Abad Medical Complex, Peshawar	marketed	Imidazole antifungal	Fungal lanosterol 14α-demethylase (CYP51)
Canesten®	Canesten®	Ache Laboratorios Farmaceuticos S.A.	marketed	Imidazole antifungal	Lanosterol 14α-demethylase (CYP51)
Ketoconazole 2%	Ketoconazole 2%	University of California, Davis	marketed	Imidazole antifungal	Fungal cytochrome P450 (CYP51 / lanosterol 14α-demethylase)
Terconazole Vaginal Suppository	Terconazole Vaginal Suppository	Hatem AbuHashim	marketed	Azole antifungal	Lanosterol 14α-demethylase (CYP51)
Voriconazole clinical practice	Voriconazole clinical practice	Instituto de Investigación Hospital Universitario La Paz	marketed	Triazole antifungal	Fungal cytochrome P450 lanosterol 14α-demethylase (CYP51)
fast itraconazole tablet	fast itraconazole tablet	University of Maryland, Baltimore	marketed	Triazole antifungal	Fungal cytochrome P450 lanosterol 14α-demethylase (CYP51)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (azole antifungal class)

Bayer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bifonazole spray once daily — Competitive Intelligence Brief. https://druglandscape.com/ci/bifonazole-spray-once-daily. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab